http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005004917-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2090f9b5fc31d6b27546425ff5f73c96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a70b05f3bdf7f6e9aaf7a41ac3aacdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96d7c8ae67bac1f23f196a4c34e84ddc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bba842fc4d37dfcaced1b55bc0c91c7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae9ff92dacc19212e0dbd6a2d6f381ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b34dcfc1b276fc8a9b491f5b842613a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6f6b387b595597e60ab0b2ed35d967e
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
filingDate 2004-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90283df1579312ce09f3601b621f38b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1a93c9f4838439dbadd5216334f5643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1486d195f1492a2e11c1c08818cc26a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea34249ed9dfb03a0f725acd4cc5c240
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_182792536b5c0dfca5cce28ce45525f1
publicationDate 2006-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005004917-A3
titleOfInvention Pharmaceutical composition for solubility enhancement of hydrophobic drugs
abstract The present invention provides a pharmaceutical composition comprising a drug and polyethylene glycol, wherein the ratio of polyethylene glycol to drug by weight is from about 0.2:1 to about 10:1, and the polyethylene glycol has a melting point of at least 37oC. The pharmaceutical compositions of the invention exhibit rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102307572-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102307572-A
priorityDate 2003-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0670162-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0826682-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635

Total number of triples: 29.